While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.

Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.47 per share for the first quarter of 2026, beating the Zacks ...

Moby Strategic Execution and Portfolio Diversification. Management attributes Q1 performance to strong executio ...

BUFFALO, N.Y. — Nicole Ellis completed her first 5k run in 2020, something that just a short time ago would've seemed almost impossible. "I am currently healthier than I have been in the last ten ...

The expanded approval was based on clinical and/or in vitro data demonstrating responsiveness across 564 variants for Alyftrek and 521 variants for Trikafta. The label expansions were granted based on ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the most profitable biotech stocks to buy now. On April 13, ...

The cost of a popular Vertex Pharmaceuticals therapy could be contributing to cystic fibrosis (CF) treatment disparities around the world, researchers argued in a recent paper. Just 12% of some ...

I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic ...

The results represent a "historic" moment in cystic fibrosis care. Vertex has announced successful results from two Phase III studies of Trikafta (elexacaftor ...

OMAHA, Nebraska (WPVI) -- A newly-approved drug is bringing hope to many people dealing with cystic fibrosis. CF slowly robs patients of their breathing, choking lungs and other organs with thick ...

Vertex Pharmaceuticals Inc. VRTX announced that the FDA has accepted its supplemental new drug application (sNDA) for the label expansion of its triple combination ...